Incyte Release: Clinical Trial Data For Combination Of Epacadostat And Opdivo (Nivolumab) Demonstrate Durable Clinical Responses In Patients With Melanoma And Head And Neck Cancer

These data supported advancing the clinical development program for epacadostat and Opdivo in these types of cancer

Combination of IDO1 enzyme inhibition plus Opdivo was generally well-tolerated in patients with select advanced solid tumors

WILMINGTON, Del. & and NEW YORK--(BUSINESS WIRE)--Incyte Corporation (Nasdaq:INCY) and Bristol-Myers Squibb Company (NYSE:BMY) today announced updated data from the ongoing Phase 1/2 ECHO-204 trial evaluating the safety and efficacy of epacadostat, Incyte’s investigational oral selective IDO1 enzyme inhibitor, in combination with Opdivo® (nivolumab), Bristol-Myers Squibb’s PD-1 immune checkpoint inhibitor, in multiple advanced solid tumors. These data will be highlighted today in an oral presentation at the American Society of Clinical Oncology (ASCO) annual meeting in Chicago, Illinois.

“The clinical responses in the ECHO-204 trial in patients with melanoma and SCCHN who were treated with the combination of epacadostat and nivolumab further underscore the rationale for studying the therapeutic utility of IDO1 enzyme inhibition plus PD-1 blockade”

Efficacy data in patients with squamous cell carcinoma of the head and neck (SCCHN), treatment-naïve advanced melanoma (MEL), ovarian cancer (OC), and colorectal cancer (CRC) will be presented today. The data show that in patients with MEL treated with epacadostat (100 mg or 300 mg) plus nivolumab (n=40), the combined objective response rate (ORR) was 63 percent (25/40), including 2 complete responses (CRs) and 23 partial responses (PRs), and the combined disease control rate (DCR) was 88 percent (35/40). In previously-treated patients with SCCHN who were treated with epacadostat (100 mg or 300 mg) plus nivolumab (n=31), the combined ORR was 23 percent (7/31), including 1 CR and 6 PRs, and the combined DCR was 61 percent (19/31). Responses for MEL and SCCHN were observed regardless of PD-L1 expression and HPV status (in SCCHN), and all responses were ongoing at the data cutoff (February 13, 2017).

Back to news